FOLD

Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing, and delivering novel high-quality medicines for rare metabolic diseases. The company's flagship commercial products include Galafold (migalastat) for the treatment of Fabry disease in adults with amenable genetic variants, and Pombiliti and Opfolda for the treatment of Pompe disease. Amicus utilizes proprietary enzyme replacement therapy, small molecule, and gene therapy platforms to develop treatments for lysosomal storage disorders and other rare diseases with significant unmet medical needs. The company's pipeline includes clinical and preclinical programs targeting additional rare diseases including Batten disease, Epidermolysis Bullosa, and other conditions. Amicus Therapeutics is headquartered in Philadelphia, Pennsylvania and has operations globally to support its research, development, manufacturing, and commercial activities.